The WHO 2022 and ICC 2022 classifications include a new AML subtype classifying AML with the presence of any of eight gene mutations, including ASXL1, BCOR, EZH2, STAG2, SF3B1, SRSF2, ZRSR2, and U2AF1 (as well as RUNX1 in the ICC 2022 classification only), as AML with myelodysplasia-related gene mutations (MR genes) [33,34,54]. This evidence concerns the gene ZRSR2 and acute myeloid leukemia.